|
Dòng
|
Nội dung
|
|
1
|
Clinical characteristics and risk factors of in-hospital mortality in patients with Takotsubo syndrome / Vu Hoang Vu, Thanh Cong Nguyen, Binh Thi Hai Nguyen, Hoa Tran, Binh Quang Truong // MedPharmRes . - 2024. - tr. 64-73. - ISSN: 2615-9139
Ký hiệu phân loại (DDC): 616.1207
Introduction: Takotsubo cardiomyopathy is a condition of transient systolic dysfunction triggered by emotional or physi- cal stress. Nowadays, Takotsubo cardiomyopathy is gaining attention and has been detected more frequently. However, there is no collected data on Vietnamese subjects. This study aims to describe the clinical characteristics of patients di- agnosed with Takotsubo cardiomyopathy and determine of rates and independent risk factors for in-hospital mortality. Methods: A retrospective andobservational study was conducted at the University Medical Center Ho Chi Minh City, involved 103 patients diagnosed with Takotsubo cardiomyopathy between January 2015 and June 2022. The diagnosis was made based on the revised Mayo Clinic diagnostic criteria. Results: The average age of the study population was 71.2±15.3 years, with females accounting for 64.1% of the patients. The most common comorbidities among the patients were hypertension (57.3%), diabetes mellitus (30.1%), ischemic heart disease (15.5%), and chronic obstructive pulmonary disease (15.5%). Acute heart failure was observed in 30.1% of the patients, while ventricular arrhythmias were present in 17.6% of cases. The majority of triggers were attributed to physical factors, including infection (37.9%), respiratory failure (18.4%), postoperative status (3.9%), and acute neurological disease (2.9%). The in-hospital mortality rate was 17.5%, and the independent risk factors were iden- tified as acute heart failure (OR=20.657, 95%CI 2.306–185.008, p=0.007) and respiratory failure (OR=10.397, 95% CI 1.117–96.795, p=0.040). Conclusions: Takotsubo cardiomyopathy patients have many comorbidities and are often triggered by physical factors. The in-hospital mortality rate is significant, with acute heart failure and respiratory failure identified as independent risk factors.
Số bản sách:
(0)
Tài liệu số:
(1)
|
|
2
|
Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient / Nam Nhut Phan, Chih-Yang Wang, Kuan-Lun Li, Chien-Fu Chen, Chung-Chieh Chiao, Han-Gang Yu, Pung-Ling Huang, Yen-Chang Lin // . - . - Vol. 9 (2018), P.6977-6992. - ISSN:
// Oncotarget. - . - . - ISSN:
New York : Impact Journals, LLC, 2018
16 p.
Ký hiệu phân loại (DDC): 660
Breast cancer is a dangerous disease that results in high mortality rates for cancer patients. Many methods have been developed for the treatment and prevention of this disease. Determining the expression patterns of certain target genes in specific subtypes of breast cancer is important for developing new therapies for breast cancer. In the present study, we performed a holistic approach to screening the mRNA expression of six members of the cell division cycle-associated gene family (CDCA) with a focus on breast cancer using the Oncomine and The Cancer Cell Line Encyclopedia (CCLE) databases. Furthermore, Gene Expression-Based Outcome for Breast Cancer Online (GOBO) was also used to deeply mine the expression of each CDCA gene in clinical breast cancer tissue and breast cancer cell lines. Finally, the mRNA expression of the CDCA genes as related to breast cancer patient survival were analyzed using a Kaplan-Meier plot. CDCA3, CDCA5, and CDCA8 mRNA expression levels were significantly higher than the control sample in both clinical tumor sample and cancer cell lines. These highly expressed genes in the tumors of breast cancer patients dramatically reduced patient survival. The interaction network of CDCA3, CDCA5, and CDCA8 with their co-expressed genes also revealed that CDCA3 expression was highly correlated with cell cycle related genes such as CCNB2, CDC20, CDKN3, and CCNB1. CDCA5 expression was correlated with BUB1 and TRIP13, while CDCA8 expression was correlated with BUB1 and CCNB1. Altogether, these findings suggested CDCA3, CDCA5, and CDCA8 could have a high potency as targeted breast cancer therapies.
Số bản sách:
(0)
Tài liệu số:
(1)
|
|
3
|
|
|
|
|
|